CN101019888A - Medicine for treating fatty liver and alcoholic hepatitis and reducing blood fat and transaminase - Google Patents
Medicine for treating fatty liver and alcoholic hepatitis and reducing blood fat and transaminase Download PDFInfo
- Publication number
- CN101019888A CN101019888A CN 200610102355 CN200610102355A CN101019888A CN 101019888 A CN101019888 A CN 101019888A CN 200610102355 CN200610102355 CN 200610102355 CN 200610102355 A CN200610102355 A CN 200610102355A CN 101019888 A CN101019888 A CN 101019888A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- liver
- fatty liver
- medicine
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 40
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 40
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 40
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 210000004369 blood Anatomy 0.000 title claims abstract description 19
- 239000008280 blood Substances 0.000 title claims abstract description 19
- 102000003929 Transaminases Human genes 0.000 title claims description 14
- 108090000340 Transaminases Proteins 0.000 title claims description 14
- 206010019728 Hepatitis alcoholic Diseases 0.000 title abstract 2
- 208000002353 alcoholic hepatitis Diseases 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title description 3
- 239000011573 trace mineral Substances 0.000 claims abstract description 17
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 17
- 150000001413 amino acids Chemical class 0.000 claims abstract description 16
- 229940088594 vitamin Drugs 0.000 claims abstract description 16
- 229930003231 vitamin Natural products 0.000 claims abstract description 16
- 235000013343 vitamin Nutrition 0.000 claims abstract description 16
- 239000011782 vitamin Substances 0.000 claims abstract description 16
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 16
- 210000004185 liver Anatomy 0.000 claims description 40
- 230000001476 alcoholic effect Effects 0.000 claims description 15
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 229940024606 amino acid Drugs 0.000 claims description 15
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 14
- 239000011575 calcium Substances 0.000 claims description 14
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 14
- 239000011777 magnesium Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 14
- 239000011669 selenium Substances 0.000 claims description 14
- 239000011701 zinc Substances 0.000 claims description 14
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 8
- 235000013922 glutamic acid Nutrition 0.000 claims description 8
- 239000004220 glutamic acid Substances 0.000 claims description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 7
- 239000004475 Arginine Substances 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 7
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 7
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 7
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 7
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 7
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 7
- 239000004473 Threonine Substances 0.000 claims description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 7
- 229930003451 Vitamin B1 Natural products 0.000 claims description 7
- 229930003779 Vitamin B12 Natural products 0.000 claims description 7
- 229930003471 Vitamin B2 Natural products 0.000 claims description 7
- 229930003268 Vitamin C Natural products 0.000 claims description 7
- 229930003316 Vitamin D Natural products 0.000 claims description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 7
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- 229930003448 Vitamin K Natural products 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 7
- 235000003704 aspartic acid Nutrition 0.000 claims description 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 7
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 7
- 229960000304 folic acid Drugs 0.000 claims description 7
- 235000019152 folic acid Nutrition 0.000 claims description 7
- 239000011724 folic acid Substances 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- 235000001968 nicotinic acid Nutrition 0.000 claims description 7
- 229960003512 nicotinic acid Drugs 0.000 claims description 7
- 239000011664 nicotinic acid Substances 0.000 claims description 7
- 229940055726 pantothenic acid Drugs 0.000 claims description 7
- 235000019161 pantothenic acid Nutrition 0.000 claims description 7
- 239000011713 pantothenic acid Substances 0.000 claims description 7
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 7
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 7
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- 229910052711 selenium Inorganic materials 0.000 claims description 7
- 229960003495 thiamine Drugs 0.000 claims description 7
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 7
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 7
- 239000004474 valine Substances 0.000 claims description 7
- 235000019155 vitamin A Nutrition 0.000 claims description 7
- 239000011719 vitamin A Substances 0.000 claims description 7
- 235000010374 vitamin B1 Nutrition 0.000 claims description 7
- 239000011691 vitamin B1 Substances 0.000 claims description 7
- 235000019163 vitamin B12 Nutrition 0.000 claims description 7
- 239000011715 vitamin B12 Substances 0.000 claims description 7
- 235000019164 vitamin B2 Nutrition 0.000 claims description 7
- 239000011716 vitamin B2 Substances 0.000 claims description 7
- 235000019158 vitamin B6 Nutrition 0.000 claims description 7
- 239000011726 vitamin B6 Substances 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- 235000019166 vitamin D Nutrition 0.000 claims description 7
- 239000011710 vitamin D Substances 0.000 claims description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 235000019168 vitamin K Nutrition 0.000 claims description 7
- 239000011712 vitamin K Substances 0.000 claims description 7
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 7
- 229940045997 vitamin a Drugs 0.000 claims description 7
- 229940011671 vitamin b6 Drugs 0.000 claims description 7
- 229940046008 vitamin d Drugs 0.000 claims description 7
- 229940046010 vitamin k Drugs 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 4
- 208000019423 liver disease Diseases 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 238000002651 drug therapy Methods 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 229960005069 calcium Drugs 0.000 description 6
- 210000003494 hepatocyte Anatomy 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 206010019668 Hepatic fibrosis Diseases 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- 229960000282 metronidazole Drugs 0.000 description 3
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 3
- 229960001661 ursodiol Drugs 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229960003563 calcium carbonate Drugs 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 description 1
- 108010058907 Tiopronin Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 101150004928 bun gene Proteins 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940126676 complementary medicines Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229950000628 silibinin Drugs 0.000 description 1
- 235000014899 silybin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004402 tiopronin Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to one kind of medicine for treating hepatosis, including fatty liver, alcoholic hepatitis, etc. and reducing blood fat. The medicine consists of amino acid 30-60 weight portions, vitamin 10-30 weight portions, and trace elements 2-5 weight portions. Experiment and clinical application show that the present invention has high curative effect.
Description
Technical field
The present invention relates to a kind of treatment hepatopathy, the medicine of blood fat reducing is specially a kind of treatment fatty liver, alcoholic liver, the medicine of blood fat reducing, transaminase lowering.
Background technology
Fatty liver is because the too much disease of liver fat accumulation that a variety of causes causes, fat content accounts for 2% to 4% of liver weight in wet base in normal person's the liver, fat content is gathered and is surpassed 5% o'clock visible fat drop of microscopically observation liver section in the liver, is referred to as fatty liver.Can be divided into alcoholic fatty liver and non-alcoholic fatty liver disease according to the cause of disease, alcoholic liver particularly, the people of modern society is because multiple bad living and diet custom, as long-term excessive drinking, to take in higher fatty acid and high confectionery thing, obesity, diabetes etc. for a long time be to cause the principal element of alcoholic liver, fatty liver.Alcoholic liver, fatty liver very easily make progress and are serious diseases such as hepatitis, hepatic fibrosis and liver cirrhosis.
The sickness rate of fatty liver rose rapidly in American-European and China in recent years, became the second largest hepatopathy that is only second to viral hepatitis.The average attack rate of (white collar personage, taxi driver, professional manager, individual proprietor, government official, high level intellectual etc.) fatty liver is 25% in some professional population; The sickness rate of fatty liver is 50% among obese people and the type ii diabetes patient; Be addicted to drink and the sickness rate of alcoholic fatty liver is 58%; The sickness rate of fatty liver is about 60% in often insomnia, tired, the sub-health population of not thinking ordinary food and drink, gastrointestinal dysfunction.The medicine that does not still have at present both at home and abroad clear and definite effectively treatment fatty liver, fatty liver treatment are primarily aimed at protopathy and adjustment diet, go on a diet and Comprehensive Treatment such as exercise.Need alleviating alcohol addiction as alcoholic liver disease, obese fatty liver need be gone on a diet.The ursodeoxycholic acid (Ursodeoxycholic acid) that also has some complementary medicines such as external use in addition, metronidazole (metronidazole, metronidazole).The product of present domestic auxiliary therapy fatty liver has ribonucleic acid, tiopronin, ademetionine, polyene phosphatidylcholine and diammonium glycyrrhizinate etc.Ursodeoxycholic acid is used for the treatment of hepatic fibrosis and the liver cirrhosis of being introduced by fatty liver, and is relevant with its immunoregulation effect to the therapeutical effect of primary biliary cirrhosis.Thereby the therapeutical effect of phosphatidylcholine alleviates mitochondrion obstacle due to the ethanol for mitochondrion provides phospholipid.Some antioxidants, plant extract such as silibinin etc. can make liver tissue lesions alleviate.But, still do not have the clear and definite medicine of effectively removing fatty liver in the market.
Summary of the invention
The present invention provides a kind of treatment fatty liver, alcoholic liver, the medicine of blood fat reducing, transaminase lowering for the weak effect problem that solves the medicine existence for the treatment of fatty liver, alcoholic liver in the prior art.
The present invention is realized by following technical scheme, a kind of treatment fatty liver, alcoholic liver, and the medicine of blood fat reducing, transaminase lowering is that the raw material of 30～60 parts in aminoacid, 10～30 parts of vitamin, 2～5 parts of trace element is formed by part by weight.
Aminoacid is, glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, agedoite, glutamic acid, glutamine, arginine, lysine, histidine, cysteine, methionine, phenylalanine, tyrosine, tryptophan, proline, in any one or a few make up with arbitrary proportion.
Vitamin is that in vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, nicotinic acid, folic acid, biotin, the pantothenic acid any one or a few makes up with arbitrary proportion.
Trace element is that among calcium Ca, magnesium Mg, ferrum Fe, selenium Se, the zinc Zn any one or a few makes up with arbitrary proportion.The concrete existence or the type of service of trace element be, as calcium carbonate, calcium hydrogen phosphate, biological calcium carbonate, and calcium lactate, calcium gluconate etc., ferrous sulfate, Ferrous gluconate, ferric citrate, ferrous fumarate etc.
The present invention is organically combined various active skull cap components, effectively removes and transport the fat of hepatocyte inner accumulated, transaminase lowering.Thereby 1, quicken transporting of fat by increasing the synthetic apolipoprotein of hepatocyte; 2, by suppressing the release of the TNF-α that fatty tissue causes, TNF-α can cause insulin resistant, thereby promoting excess fatty acids to form to induce CYP2E1 to express strengthens, cause the activation of hepatic necrosis and sternzellen, and then cause hepatic fibrosis; 3, by suppressing the release of KUPFFER cell TGF-β, avoid causing the activation of liver astrocyte, activation causes hepatic fibrosis thereby the release of TGF-β can be quickened the liver astrocyte; 4, cause the peroxide and the living radical of hepatocyte oxidative damage by removing, avoid hepatocyte impaired and promote impaired hepatocyte to recover.
Experiment and clinical test results show that the present invention is respond well to removing fatty liver, and cure rate and obvious effective rate reach 83%.Diabetes merge Patients with Fatty Liver and disappear with the clean back of liver fatty liver, variation does not make significant difference to fasting glucose in the present invention, can effectively reduce monoglyceride (27%), effectively reduce glutamic acid rotating phthalein enzyme, glutamate pyruvate transaminase and BUN, but do not make significant difference reducing LDL-CH and HDL-CH, TC, CR and uric acid variation.
The variation of patient's fatty liver sees the following form 1 before and after taking the present invention
| Severe | Moderate | Slightly | Normally | Cure and obvious effective rate % | |
| Before the |
2 | ?23 | ?3 | ?5 | |
| After the |
0 | ?5 | ?13 | ?15 | ?83 |
Table 2 is taken medicine of the present invention front and back liver function, blood fat, renal function mensuration
| Detect index | Before taking | After taking | Change before and after taking | Rate of change % before and after taking | |
| Liver function | GGT | ?70 | ?45 | -25 | -36 |
| ALT | ?66 | ?35 | -31 | -47 | |
| Blood fat | TC | ?5.8 | ?5.6 | -0.2 | -3 |
| TG | ?2.3 | ?1.6 | -0.7 | -30 | |
| The kidney merit | BUN | ?6.99 | ?4.26 | -2.73 | -39 |
| Cr | ?73 | ?76 | ?3 | ?4 | |
Zoopery
1, the present invention to rat feeding ethanol after to reducing the effect of blood alcohol concentration, see accompanying drawing 1
2, the present invention can significantly suppress in the inductive blood of endotoxin LPS TNF-α and raises, and two groups of rat LPS are induced the influence that produces TNF-α, sees accompanying drawing 2, and explanation can obviously reduce tumor necrosis factor level (TNF-α) in the blood that LPS induces generation.
3, the present invention raises the influence of glutamic oxaloacetic transaminase, GOT AST level in the ethanol bleeding from anus to rat stomach, sees Fig. 3.Zoopery shows that the present invention has obvious protective effect to the rat liver cell, gives the obviously recovery of acceleration of alcohol hepatocyte injury of medicine of the present invention, and quickens the serum transaminase level and recover; The present invention can obviously reduce rat serum, urine, excrement, expired gas and gastric content alcohol concentration, can be by activating or promoting that first-pass metabolism mechanism minimizing ethanol absorbs in gastrointestinal or the liver, promote alcohol metabolism, can obviously reduce LPS and induce the level that produces TNF-α.
Model case
1, Mr. A, 45 years old age, suffer from the moderate fatty liver, liver recovers normal after taking the present invention, and fatty liver is removed fully, and Fig. 4 is a B ultrasonic image of taking the preceding liver of the present invention, and Fig. 5 is the B ultrasonic image through liver after the Drug therapy of the present invention.
2, Mrs B, 42 years old age, suffer from the moderate fatty liver, liver recovers normal after taking the present invention, and fatty liver is removed fully, and Fig. 6 is a B ultrasonic image of taking the preceding liver of the present invention, and Fig. 7 is the B ultrasonic image through liver after the Drug therapy of the present invention.
3, Mr. C, 64 years old age, suffer from severe fatty liver, diabetes, the B ultrasonic image of liver is anticipated as shown in Figure 8, and normal through liver after taking this Drug therapy, fatty liver is removed fully, and glycemic control is stable, as schematically shown in Figure 9.
4, Mr. D, 41 years old age, occupation, cadre; Suffers from the moderate fatty liver; Figure 10 is a B ultrasonic image of taking the preceding liver of the present invention, often becomes a full member through liver after taking this Drug therapy, and fatty liver is removed fully, as schematically shown in Figure 11.
Description of drawings
Fig. 1 for the present invention to rat feeding ethanol after the influence of first-pass metabolism
Fig. 2 is for inducing the influence that produces TNF-α to two groups of rat LPS
Fig. 3 raises the influence of glutamic oxaloacetic transaminase, GOT AST level in the ethanol bleeding from anus to rat stomach for the present invention
Fig. 4 takes the B ultrasonic impression of the preceding liver of the present invention for patient 1
Fig. 5 is the B ultrasonic impression of patient 1 through liver after the Drug therapy of the present invention
Fig. 6 takes the B ultrasonic impression of the preceding liver of the present invention for patient 2
Fig. 7 is the B ultrasonic impression of patient 2 through liver after the Drug therapy of the present invention
Fig. 8 takes the B ultrasonic impression of the preceding liver of the present invention for patient 3
Fig. 9 is the B ultrasonic impression of patient 3 through liver after the Drug therapy of the present invention
Figure 10 takes the B ultrasonic impression of the preceding liver of the present invention for patient 4
Figure 11 is the B ultrasonic impression of patient 4 through liver after the Drug therapy of the present invention
The specific embodiment
A kind of treatment fatty liver, alcoholic liver, the medicine of blood fat reducing, transaminase lowering is that aminoacid 30 grams, vitamin 10 grams, trace element 2 grams are formed by part by weight.
Aminoacid is that any vitamin in glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, agedoite, glutamic acid, glutamine, arginine, lysine, histidine, cysteine, methionine, phenylalanine, tyrosine, tryptophan, the proline is any in vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, nicotinic acid, folic acid, biotin, the pantothenic acid
Trace element is any among calcium Ca, magnesium Mg, ferrum Fe, selenium Se, the zinc Zn.Get the forming agent that above-mentioned each raw material adds 30～40 parts again and can make tablet, dosage forms such as pill, each dosage form is produced and is common process, preparing tablet as dry granulation sieves each raw material pulverizing exactly and granulates then after back and the binding agent mixing that tabletting gets final product, perhaps adopt wet granulation, with disintegrating agent, wetting agent and each raw material mixing after drying, granulate, tabletting gets final product.
A kind of treatment fatty liver, alcoholic liver, the medicine of blood fat reducing, transaminase lowering is that aminoacid 60 grams, vitamin 30 grams, trace element 5 grams are formed by part by weight.
Aminoacid is, in glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, agedoite, glutamic acid, glutamine, arginine, lysine, histidine, cysteine, methionine, phenylalanine, tyrosine, tryptophan, the proline any two mix with arbitrary proportion
Vitamin is that in vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, nicotinic acid, folic acid, biotin, the pantothenic acid any two mix with arbitrary proportion,
Trace element is that among calcium Ca, magnesium Mg, ferrum Fe, selenium Se, the zinc Zn any two mix with arbitrary proportion.Taking by weighing above-mentioned each mixed raw material becomes capsule to get final product.
A kind of treatment fatty liver, alcoholic liver, the medicine of blood fat reducing, transaminase lowering by part by weight is 40 parts in aminoacid, 25 parts of vitamin, 3.5 parts of compositions of trace element.Every part 1000 gram.
Aminoacid is, wantonly five kinds in glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, agedoite, glutamic acid, glutamine, arginine, lysine, histidine, cysteine, methionine, phenylalanine, tyrosine, tryptophan, the proline are mixed with arbitrary proportion
Vitamin is that wantonly five kinds in vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, nicotinic acid, folic acid, biotin, the pantothenic acid mix with arbitrary proportion,
Trace element is that wantonly three kinds among calcium Ca, magnesium Mg, ferrum Fe, selenium Se, the zinc Zn mix with arbitrary proportion.
A kind of treatment fatty liver, alcoholic liver, the medicine of blood fat reducing, transaminase lowering by part by weight is 55 parts in aminoacid, 20 parts of vitamin, 4 parts of compositions of trace element.Every part 100 gram.
Aminoacid is, wantonly eight kinds in glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, agedoite, glutamic acid, glutamine, arginine, lysine, histidine, cysteine, methionine, phenylalanine, tyrosine, tryptophan, the proline are mixed with arbitrary proportion
Vitamin is that wantonly eight kinds in vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, nicotinic acid, folic acid, biotin, the pantothenic acid mix with arbitrary proportion,
Trace element is that wantonly three kinds among calcium Ca, magnesium Mg, ferrum Fe, selenium Se, the zinc Zn mix with arbitrary proportion.
A kind of treatment fatty liver, alcoholic liver, the medicine of blood fat reducing, transaminase lowering by part by weight is 50 parts in aminoacid, 15 parts of vitamin, 3 parts of compositions of trace element.Every part 10 gram.
Aminoacid is, glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, agedoite, glutamic acid, glutamine, arginine, lysine, histidine, cysteine, methionine, phenylalanine, tyrosine, tryptophan, whole in the proline mix with arbitrary proportion, vitamin is a vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, nicotinic acid, folic acid, biotin, whole in the pantothenic acid mix with arbitrary proportion
Trace element is that whole among calcium Ca, magnesium Mg, ferrum Fe, selenium Se, the zinc Zn mix with arbitrary proportion.
Claims (2)
1, a kind of treatment fatty liver, alcoholic liver, blood fat reducing, the medicine of transaminase lowering, it is characterized in that: be by part by weight, 30～60 parts in aminoacid, 10～30 parts of vitamin, the raw material that trace element is 2～5 parts is formed, aminoacid is, glycine, alanine, valine, leucine, isoleucine, serine, threonine, aspartic acid, agedoite, glutamic acid, glutamine, arginine, lysine, histidine, cysteine, methionine, phenylalanine, tyrosine, tryptophan, proline, in any one or a few mix with arbitrary proportion
Vitamin is that in vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, nicotinic acid, folic acid, biotin, the pantothenic acid any one or a few mixes with arbitrary proportion,
Trace element is that among calcium Ca, magnesium Mg, ferrum Fe, selenium Se, the zinc Zn any one or a few mixes with arbitrary proportion.
2, the medicine of treatment fatty liver according to claim 1, alcoholic liver, blood fat reducing, transaminase lowering is characterized in that: be that the raw material of 50 parts in aminoacid, 15 parts of vitamin, 3 parts of trace element is formed by part by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610102355 CN101019888A (en) | 2006-12-28 | 2006-12-28 | Medicine for treating fatty liver and alcoholic hepatitis and reducing blood fat and transaminase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610102355 CN101019888A (en) | 2006-12-28 | 2006-12-28 | Medicine for treating fatty liver and alcoholic hepatitis and reducing blood fat and transaminase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101019888A true CN101019888A (en) | 2007-08-22 |
Family
ID=38707814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610102355 Pending CN101019888A (en) | 2006-12-28 | 2006-12-28 | Medicine for treating fatty liver and alcoholic hepatitis and reducing blood fat and transaminase |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101019888A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869687A (en) * | 2010-06-10 | 2010-10-27 | 银小龙 | Medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase |
| CN101905015A (en) * | 2010-07-19 | 2010-12-08 | 银小龙 | Medicine capable of decomposing alcohol, preventing drunkenness and protecting liver |
| CN102228300A (en) * | 2011-06-28 | 2011-11-02 | 常连第 | Stress-protected special nutrient functional drink oral liquid |
| CN103143003A (en) * | 2013-03-22 | 2013-06-12 | 武汉工程大学 | Healthcare product for relieving hangover and protecting liver |
| CN104055773A (en) * | 2014-07-03 | 2014-09-24 | 万红贵 | Blood-fat reducing composition and application thereof |
| CN106420784A (en) * | 2016-12-23 | 2017-02-22 | 郑州莉迪亚医药科技有限公司 | Medicinal composition for treating fatty liver |
| CN106727647A (en) * | 2016-12-23 | 2017-05-31 | 郑州莉迪亚医药科技有限公司 | A kind of medicine for treating fatty liver |
| CN109966308A (en) * | 2019-05-14 | 2019-07-05 | 深圳市众康动保科技有限公司 | A kind of dedicated liver slice prescription of dog cat |
| CN110198709A (en) * | 2017-02-17 | 2019-09-03 | 普惠德生技股份有限公司 | Composition containing Ferrous amino acid chelates is used to manufacture the purposes of the pharmaceuticals for the treatment of dysfunction of liver |
| US10750771B2 (en) | 2011-06-23 | 2020-08-25 | Innovafood Ab | Food supplement comprising amino acid and chromium |
-
2006
- 2006-12-28 CN CN 200610102355 patent/CN101019888A/en active Pending
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869687B (en) * | 2010-06-10 | 2011-11-16 | 银小龙 | Medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase |
| CN101869687A (en) * | 2010-06-10 | 2010-10-27 | 银小龙 | Medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase |
| CN101905015A (en) * | 2010-07-19 | 2010-12-08 | 银小龙 | Medicine capable of decomposing alcohol, preventing drunkenness and protecting liver |
| US10750771B2 (en) | 2011-06-23 | 2020-08-25 | Innovafood Ab | Food supplement comprising amino acid and chromium |
| US11937624B2 (en) | 2011-06-23 | 2024-03-26 | Innovafood Ab | Food composition |
| CN102228300A (en) * | 2011-06-28 | 2011-11-02 | 常连第 | Stress-protected special nutrient functional drink oral liquid |
| CN102228300B (en) * | 2011-06-28 | 2013-08-21 | 常连第 | Stress-protected special nutrient functional drink oral liquid |
| CN103143003B (en) * | 2013-03-22 | 2014-03-26 | 武汉工程大学 | Healthcare product for relieving hangover and protecting liver |
| CN103143003A (en) * | 2013-03-22 | 2013-06-12 | 武汉工程大学 | Healthcare product for relieving hangover and protecting liver |
| CN104055773B (en) * | 2014-07-03 | 2016-05-25 | 万红贵 | A kind of blood-fat reducing composition and application thereof |
| CN104055773A (en) * | 2014-07-03 | 2014-09-24 | 万红贵 | Blood-fat reducing composition and application thereof |
| CN106420784A (en) * | 2016-12-23 | 2017-02-22 | 郑州莉迪亚医药科技有限公司 | Medicinal composition for treating fatty liver |
| CN106727647A (en) * | 2016-12-23 | 2017-05-31 | 郑州莉迪亚医药科技有限公司 | A kind of medicine for treating fatty liver |
| CN110198709A (en) * | 2017-02-17 | 2019-09-03 | 普惠德生技股份有限公司 | Composition containing Ferrous amino acid chelates is used to manufacture the purposes of the pharmaceuticals for the treatment of dysfunction of liver |
| CN109966308A (en) * | 2019-05-14 | 2019-07-05 | 深圳市众康动保科技有限公司 | A kind of dedicated liver slice prescription of dog cat |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101019888A (en) | Medicine for treating fatty liver and alcoholic hepatitis and reducing blood fat and transaminase | |
| KR20080091743A (en) | Pharmaceutical and food compositions for preventing or treating arthritis comprising lactic acid bacteria and collagen as active ingredients | |
| CN104855956A (en) | Medical formula food for insomnia | |
| US10821149B2 (en) | Composition and the use thereof | |
| AU2015384083B2 (en) | Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome | |
| CN101869687B (en) | Medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase | |
| CN104187613A (en) | Total-nutrient formulated food for patients with insomnia | |
| CN103479635A (en) | Pharmaceutical composition used for preventing and treating non-alcoholic fatty liver disease and application thereof | |
| ES2861023T3 (en) | Reducing composition of fat in the blood and its application | |
| CN101905015B (en) | Medicine capable of decomposing alcohol, preventing drunkenness and protecting liver | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| KR20140016863A (en) | Anti-fatigue composition of plant material and preparation method, use and products thereof | |
| CN102512485A (en) | Traditional Chinese medicine for treating acute hepatitis, chronic hepatitis and hepatic fibrosis | |
| CN109965072A (en) | A kind of pressed candy and the preparation method and application thereof conserving liver | |
| CN102784137B (en) | A kind of Anti-obesity drug composition and application thereof | |
| JP2007217345A (en) | Pearl vinegar and method for producing the same | |
| CN116268414A (en) | Composition for improving gastrointestinal function and preventing constipation and application thereof | |
| CN101816708B (en) | Chinese medicinal composition for curing rheumatism and preparation method thereof | |
| JP4460234B2 (en) | Diet food | |
| WO2010037255A1 (en) | The usage of ginseng and gynostemma pentaphyllum compound preparation in manufacture of medicaments with the effects of lipid regulation and blood-sugar regulation | |
| CN101766717B (en) | Composition for disintoxicating and sobering | |
| CN104721808A (en) | Pharmaceutical composition for treating neonatal jaundice | |
| KR20200079276A (en) | Use of cyanobacteria biomass in the treatment of hepatitis B virus infection | |
| CN102631488B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: XINZHOU YINHUI BIOCHEMISTRY SCIENCE AND TECHNOLOGY Free format text: FORMER OWNER: YIN XIAOLONG Effective date: 20091211 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20091211 Address after: The postcode of Fen Jie street, Xinzhou Development Zone, Shanxi Province, China: 034000 Applicant after: Xinzhou Yinhui Biochemical Technology Co., Ltd. Address before: Shanxi Province, Xinzhou City, Da Dong Jie Jiao Jia Bei Xiang, Xinfu District Grain Bureau dormitory post encoding: 034000 Applicant before: Yin Xiaolong |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20070822 |